CA2460704A1 - Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes - Google Patents
Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes Download PDFInfo
- Publication number
- CA2460704A1 CA2460704A1 CA002460704A CA2460704A CA2460704A1 CA 2460704 A1 CA2460704 A1 CA 2460704A1 CA 002460704 A CA002460704 A CA 002460704A CA 2460704 A CA2460704 A CA 2460704A CA 2460704 A1 CA2460704 A1 CA 2460704A1
- Authority
- CA
- Canada
- Prior art keywords
- lysine
- serine
- sequence seq
- acetylated
- phosphorylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000001363 autoimmune Effects 0.000 title claims abstract description 16
- 230000007170 pathology Effects 0.000 title claims abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 138
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 79
- 230000004481 post-translational protein modification Effects 0.000 title description 6
- 150000001413 amino acids Chemical class 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 238000012986 modification Methods 0.000 claims abstract description 9
- 230000004048 modification Effects 0.000 claims abstract description 7
- 230000021736 acetylation Effects 0.000 claims abstract description 6
- 238000006640 acetylation reaction Methods 0.000 claims abstract description 6
- 230000026731 phosphorylation Effects 0.000 claims abstract description 6
- 238000006366 phosphorylation reaction Methods 0.000 claims abstract description 6
- 230000001323 posttranslational effect Effects 0.000 claims abstract description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 143
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 136
- 239000004472 Lysine Substances 0.000 claims description 136
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 131
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 126
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 241001529936 Murinae Species 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 210000001324 spliceosome Anatomy 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 101710191279 U1 small nuclear ribonucleoprotein 70 kDa Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 2
- 108010061100 Nucleoproteins Proteins 0.000 claims description 2
- 102000011931 Nucleoproteins Human genes 0.000 claims description 2
- 108010047956 Nucleosomes Proteins 0.000 claims description 2
- 102000004389 Ribonucleoproteins Human genes 0.000 claims description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- -1 acids amino acids Chemical class 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 230000000366 juvenile effect Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims 2
- 101000690100 Homo sapiens U1 small nuclear ribonucleoprotein 70 kDa Proteins 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000054514 human SNRNP70 Human genes 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000001623 nucleosome Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 235000018977 lysine Nutrition 0.000 description 71
- 241000699670 Mus sp. Species 0.000 description 29
- 206010025135 lupus erythematosus Diseases 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 15
- 101001108927 Rattus norvegicus Nuclear pore complex protein Nup155 Proteins 0.000 description 12
- 102100031876 SRC kinase signaling inhibitor 1 Human genes 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 238000001819 mass spectrum Methods 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- LSLBZWAEEUGETG-GGVFYUGVSA-N p140 peptide Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)C(=O)[C@H](CONCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NP(O)(O)=O)C1=CN=CN1 LSLBZWAEEUGETG-GGVFYUGVSA-N 0.000 description 4
- 108010061749 spliceosomal peptide P140 Proteins 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000004598 Small Nuclear Ribonucleoproteins Human genes 0.000 description 3
- 108010003165 Small Nuclear Ribonucleoproteins Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000003172 anti-dna Effects 0.000 description 3
- 230000001934 delay Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HQLBYVWJOXITAM-NRFANRHFSA-N (2s)-6-acetamido-2-(9h-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)C)C(O)=O)C3=CC=CC=C3C2=C1 HQLBYVWJOXITAM-NRFANRHFSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- FLYANDHDFRGGTM-PYJNHQTQSA-N Arg-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N FLYANDHDFRGGTM-PYJNHQTQSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010093013 HLA-DR1 Antigen Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000854908 Homo sapiens WD repeat-containing protein 11 Proteins 0.000 description 1
- JXMSHKFPDIUYGS-SIUGBPQLSA-N Ile-Glu-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N JXMSHKFPDIUYGS-SIUGBPQLSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- PVSPJQWHEIQTEH-JYJNAYRXSA-N Met-Val-Tyr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PVSPJQWHEIQTEH-JYJNAYRXSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- BNBBNGZZKQUWCD-IUCAKERBSA-N Pro-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 BNBBNGZZKQUWCD-IUCAKERBSA-N 0.000 description 1
- 101710188313 Protein U Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- WSTIOCFMWXNOCX-YUMQZZPRSA-N Ser-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N WSTIOCFMWXNOCX-YUMQZZPRSA-N 0.000 description 1
- NNFMANHDYSVNIO-DCAQKATOSA-N Ser-Lys-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NNFMANHDYSVNIO-DCAQKATOSA-N 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- XGEUYEOEZYFHRL-KKXDTOCCSA-N Tyr-Ala-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 XGEUYEOEZYFHRL-KKXDTOCCSA-N 0.000 description 1
- 102100020705 WD repeat-containing protein 11 Human genes 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 108010048994 glycyl-tyrosyl-alanine Proteins 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 150000002668 lysine derivatives Chemical class 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0112041A FR2829768B1 (fr) | 2001-09-18 | 2001-09-18 | Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes |
| FR01/12041 | 2001-09-18 | ||
| PCT/FR2002/003186 WO2003025014A2 (fr) | 2001-09-18 | 2002-09-18 | Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2460704A1 true CA2460704A1 (fr) | 2003-03-27 |
Family
ID=8867384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002460704A Abandoned CA2460704A1 (fr) | 2001-09-18 | 2002-09-18 | Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7872098B1 (enExample) |
| EP (2) | EP2338908A1 (enExample) |
| JP (1) | JP4160505B2 (enExample) |
| AU (1) | AU2002362383B2 (enExample) |
| CA (1) | CA2460704A1 (enExample) |
| FR (1) | FR2829768B1 (enExample) |
| WO (1) | WO2003025014A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030186849A1 (en) * | 2001-09-06 | 2003-10-02 | Zimmer Robert H. | Modified peptides and their use for the treatment of autoimmune diseases |
| FR2931360B1 (fr) * | 2008-05-20 | 2012-05-18 | Centre Nat Rech Scient | Nanoparticules contenant un peptide, vecteurs les contenant et utilisations pharmaceutiques desdits nanoparticules et vecteurs |
| IN2014MN01376A (enExample) | 2011-12-13 | 2015-04-17 | Centre Nat Rech Scient | |
| US10213482B2 (en) | 2014-12-12 | 2019-02-26 | Immupharma France Sa | Methods of treating chronic inflammatory diseases |
| US20210308211A1 (en) * | 2020-03-29 | 2021-10-07 | Immupharma France Sa | Method of treating viral infections |
| CN119241701A (zh) * | 2024-09-27 | 2025-01-03 | 珠海丽禾医疗诊断产品有限公司 | U1-70k结合蛋白、制备方法和应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030186849A1 (en) * | 2001-09-06 | 2003-10-02 | Zimmer Robert H. | Modified peptides and their use for the treatment of autoimmune diseases |
-
2001
- 2001-09-18 FR FR0112041A patent/FR2829768B1/fr not_active Expired - Lifetime
-
2002
- 2002-09-18 EP EP10183969A patent/EP2338908A1/fr not_active Withdrawn
- 2002-09-18 EP EP02798771A patent/EP1427755A2/fr not_active Ceased
- 2002-09-18 US US10/489,967 patent/US7872098B1/en active Active
- 2002-09-18 WO PCT/FR2002/003186 patent/WO2003025014A2/fr not_active Ceased
- 2002-09-18 JP JP2003528859A patent/JP4160505B2/ja not_active Expired - Lifetime
- 2002-09-18 AU AU2002362383A patent/AU2002362383B2/en not_active Expired
- 2002-09-18 CA CA002460704A patent/CA2460704A1/fr not_active Abandoned
-
2010
- 2010-10-27 US US12/913,232 patent/US8475800B2/en not_active Expired - Lifetime
-
2013
- 2013-06-11 US US13/914,997 patent/US20140004136A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8475800B2 (en) | 2013-07-02 |
| FR2829768B1 (fr) | 2003-12-12 |
| EP2338908A1 (fr) | 2011-06-29 |
| JP4160505B2 (ja) | 2008-10-01 |
| US20120149652A1 (en) | 2012-06-14 |
| FR2829768A1 (fr) | 2003-03-21 |
| JP2005510469A (ja) | 2005-04-21 |
| US7872098B1 (en) | 2011-01-18 |
| WO2003025014A2 (fr) | 2003-03-27 |
| US20140004136A1 (en) | 2014-01-02 |
| WO2003025014A3 (fr) | 2004-02-19 |
| EP1427755A2 (fr) | 2004-06-16 |
| AU2002362383B2 (en) | 2008-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7560100B2 (en) | Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases | |
| US20070059798A1 (en) | Polypeptides useful for molecular weight determinations | |
| WO2007146331A1 (en) | Tannate salt form of polypeptide mixtures, their preparation and use | |
| US20080194462A1 (en) | Methods and Compositions for Treatment of Autoimmune Diseases | |
| JPH10509172A (ja) | ヒトミエリン塩基性タンパク質のペプチドアナログを用いた多発性硬化症の処置のための方法 | |
| US20140004136A1 (en) | Phosphorylated derivatives of a u1-70k peptide and their use in the treatment of autoimmune pathologies | |
| KR0159046B1 (ko) | 포유류의 자기면역 포도막망막염의 치료 또는 예방방법 | |
| JP3307649B2 (ja) | 自己免疫疾患の進行を阻害するための処理方法 | |
| CA2459811C (en) | Modified peptides and their use for the treatment of autoimmune diseases | |
| Briand et al. | Emerging peptide therapeutics for inflammatory autoimmune diseases | |
| AU2014291149B2 (en) | Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor | |
| AU2001247965A1 (en) | Therapeutic and diagnostic methods for ulcerative colitis and associated disorders | |
| JP4642469B2 (ja) | カルシニューリンの恒常的活性化阻害剤 | |
| US20230414732A1 (en) | Compositions of embedded epitope random peptides (eerp) for treatment of immune-mediated conditions, and methods of use | |
| JPH10509693A (ja) | Ｍｈｃ−ペプチド複合体の調製法 | |
| EA019358B1 (ru) | Аллель- и изотип-специфическая интервенция в ассоциированные с аутоиммунными заболеваниями молекулы класса ii мнс при помощи пептидов | |
| EP2279744A2 (en) | ApoE mimetic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |
Effective date: 20130320 |